Xilas Medical Inc. receives Phase II funding from the National Institutes of Health for diabetes telemedicine grant

San Antonio 04 April 2005Xilas Medical Inc.'s telemedicine grant has been approved for Phase II funding from the National Institutes of Health (NIH). The grant is for $880.000 over 24 months and allows Xilas to conduct clinical trials on its TempTouch RM, an infrared temperature remote monitoring (RM) device for diabetic patients. A Phase I NIH-sponsored trial was completed in late 2003 and proved that the TempTouch RM can be used as an effective tool for capturing the medical data and sending it over a modem.


The TempTouch RM is a device that diabetes patients use at home and stand on like a bathroom scale. It measures foot temperatures and the patient's weight, loads the data into an on-board computer, and transmits the information via the phone/Internet to the doctor's office or a central monitoring facility. The daily measurements are monitored for any potential problems. Elevated foot temperatures can be a sign of inflammation and potential ulceration, and a sudden increase in weight is an indication of impending heart problems in diabetic patients with congestive heart failure.

"The TempTouch RM is our first product in the area of telemedicine, and it's a way that information technology can be used to save lives and money in the future of health care", stated Don Lawson, CEO of Xilas Medical Inc. "This device is designed for the high-risk diabetes patient who can't check their temperature measurements using a handheld device due to age, blindness, disability, or obesity. These are people for whom an ulcer would mean devastating consequences, including amputation and potential loss of life. With the TempTouch RM, the physician can get daily reports on the patient and detect potential ulcers before they occur, truly improving outcomes and quality of life."

Xilas will run a one-year clinical trial where the TempTouch RM will be placed into the homes of 50 diabetic patients who are at high risk for foot complications. The use of the TempTouch RM in a home setting provides diabetes patients with a way to participate in their own care and prevention and take corrective action before problems spiral beyond control and high medical costs become unavoidable. Xilas has been issued two United States patents on the TempTouch RM. To date, the company has received a total of $3,6 million from the NIH for product testing and clinical trials on its family of products. Xilas has also received two 510(k) approvals from the Food and Drug Administration and has begun marketing its products.

Xilas Medical Inc. develops patented medical devices, which are founded on evidence-based medicine and clinically proven to reduce foot amputations in diabetic patients. Xilas' friction reduction, nerve damage assessment, and temperature management products dramatically decrease health care costs by preventing acute problems and providing patients and doctors with an early warning system of potential foot-related complications. Studies show that Xilas products have an unusually high level of compliance among diabetic patients and that using the Xilas TempTouch reduces the chances of foot amputation by up to 85 percent. By focusing on prevention, Xilas is bringing about social change in the management of diabetes.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]